Fate TherapeuticsFATE
FATE
About: Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Employees: 181
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
967% more call options, than puts
Call options by funds: $64K | Put options by funds: $6K
0% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 40
5.01% less ownership
Funds ownership: 89.18% [Q4 2024] → 84.17% (-5.01%) [Q1 2025]
17% less funds holding
Funds holding: 157 [Q4 2024] → 130 (-27) [Q1 2025]
54% less capital invested
Capital invested by funds: $166M [Q4 2024] → $76.2M (-$90M) [Q1 2025]
57% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 42
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2
57%
upside
Avg. target
$3
136%
upside
High target
$4
215%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Barclays Peter Lawson | 57%upside $2 | Overweight Maintained | 14 May 2025 |
Baird Jack Allen | 215%upside $4 | Neutral Maintained | 14 May 2025 |
Financial journalist opinion
Based on 5 articles about FATE published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
Neutral
GlobeNewsWire
4 days ago
Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up continues in drug-free Definition of Remission in SLE (DORIS)
Positive
Zacks Investment Research
5 days ago
Top Cancer Stocks to Supercharge Your 2025 Portfolio
Pfizer, Novartis and Fate Therapeutics are making bold oncology moves as demand surges for next-gen cancer therapies.
Neutral
GlobeNewsWire
2 weeks ago
Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years' experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy's appointment.
Neutral
GlobeNewsWire
2 weeks ago
Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE) Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe systemic lupus erythematosus (SLE)
Positive
Zacks Investment Research
1 month ago
Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus
FATE incurs a narrower-than-expected loss in the first quarter. The company's innovative pipeline remains in focus.
Negative
Zacks Investment Research
1 month ago
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Fate Therapeutics (FATE) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.47 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates
Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June
Negative
Seeking Alpha
1 month ago
Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector
I've had a mixed experience with Fate Therapeutics, initially noting rallies but later observing a significant 75% decline, questioning market enthusiasm. Revisiting FATE after a year, I aim to determine if the market's lack of interest is justified or a broader cell therapy sector issue. The article explores FATE's pipeline updates, financial overview, and strengths and risks to provide a comprehensive investment thesis.
Neutral
GlobeNewsWire
1 month ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on May 1, 2025 the Company granted restricted stock units (RSUs) representing 30,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company's Board of Directors and granted under the Company's Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% of the shares underlying each RSU award vesting on each anniversary of the grant date, subject to the employees being continuously employed by the Company through each vesting date.
Charts implemented using Lightweight Charts™